A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, Zhiwei Wu
Abstract
is a potential candidate for both the prevention and treatment of SARS-CoV-2 through respiratory administration.
Topics & Concepts
Nasal administrationNeutralizationMedicineVirologyPotencyIn vivoVirusGlycoproteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCoronavirus disease 2019 (COVID-19)In vitroBiologyDiseaseInternal medicineMolecular biologyBiochemistryInfectious disease (medical specialty)BiotechnologySARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approaches